Skip to main content

Advertisement

Table 1 Characteristics of patients with JIA and healthy children at baseline and 2-year follow-up*

From: Serum levels of osteoprotegerin and receptor activator of nuclear factor -κB ligand in children with early juvenile idiopathic arthritis: a 2-year prospective controlled study

  Baseline 2 year follow-up
  JIA patients(n = 90) Controls(n = 90) JIA patients(n = 90) Controls(n = 90)
Characteristics     
Female, n (%) 56 (62%) 56 (62%) 56 (62%) 56 (62%)
Age, mean (SD) years 10.1 (3.2) 10.1 (3.2) 12.1 (3.2) 12.2 (3.2)
Disease-onset type, n (%)     
   Oligoarthritis, persistent 48 (53%) - 48 (53%) -
   Oligoarthritis, extended 11 (12%) - 11 (12%) -
   Polyarthritis, RF negative 28 (31%) - 28 (31%) -
   Polyarthritis, RF positive 3 (3%) - 3 (3%) -
Disease duration, mean (SD) months 19.4 (12.3) - 44.3 (14.2) -
No. of joints with active disease, mean (SD) † 2.2 (3.5) - 1.3 (4.2) -
No. of joints with restricted mobility, mean (SD) † 1.7 (2.6) - 1.2 (2.2) -
Radiographic score, mean (SD) ‡ 1.7 (0.6) - 1.8 (0.6) -
Radiographic erosions, n (%) § 3 (3%) - 5 (6%) -
Radiographic progression, n (%)¶ - - 9 (10%) -
Total body BMC Z-score < -1, n (%) 10 (11%) 9 (10%) 20 (22%) 12 (13%)
Disease-modifying antirheumatic drugs, current use, n (%) 48 (53%) - 37 (41%) # -
Non-steroidal anti-inflammatory drugs, current use, n (%) 68 (76%)   43 (48%)  
Oral corticosteroids **     
   Current use, n (%) 17 (19%) - 8 (9%) -
Dosage, mean (SD) mg/day 11.2 (7.1) - 6.7 (5.9) -
   Ever used, n (%) 27 (30%) - 31 (34%) -
Cumulative dose, mean (SD) mg 1234 (1328) - 1919 (2062) -
Cumulative dose, mean (SD) mg/kg of body weight 38 (42) - 52 (65) -
  1. * Because of rounding, not all percentages total 100. JIA = juvenile idiopathic arthritis; RF = rheumatoid factor; BMC = bone mineral content.
  2. † Sixty-nine joints were evaluated.
  3. ‡ Highest registered score from a range of 0 = best to 5 = worst.
  4. § Erosions = radiographic grade 3 or higher.
  5. ¶ Increase in radiographic grade from baseline to follow-up.
  6. # Methotrexate (n = 24), hydroxychloroqine (n = 8), methotrexate plus hydroxychloroqine (n = 3), methotrexate plus sulfasalazine (n = 1) and methotrexate plus etanercept (n = 1).
  7. ** Prednisolone. None of the patients had taken methylprednisolone.